Showing results (31-40 of 44) with videos related to
Sort By:
Pageof 5
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.Clinical and Translational Science|July 25, 2018
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist TherapyHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.Journal of Viral Hepatitis|February 11, 2019
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infectionEric Lawitz, Fred Poordad, Leah J Anderson, et al.Journal of Virology|July 22, 2011
The TRIM5 gene modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeysWendy W Yeh, Srinivas S Rao, So-Yon Lim, et al.JAMA|March 14, 2022
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical TrialAnil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al.Journal of Virology|March 16, 2012
Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infectionTakuya Yamamoto, Matthew J Johnson, David A Price, et al.The Journal of Experimental Medicine|May 6, 2009
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1Brandon F Keele, Hui Li, Gerald H Learn, et al.Antimicrobial Agents and Chemotherapy|February 13, 2019
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy VolunteersHwa-Ping Feng, Luzelena Caro, Christine Fandozzi, et al.Cell Reports. Medicine|August 17, 2022
Antibody therapy reverses biological signatures of COVID-19 progressionM Cyrus Maher, Leah B Soriaga, Anil Gupta, et al.Clinical Therapeutics|April 29, 2018
Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3Wendy W Yeh, Iain P Fraser, Patricia Jumes, et al.Pageof 5